1. Youd E, Moore L. COVID-19 autopsy in people who died in community settings: the first series. J Clin Pathol 2020;73:840–844.
2. Mall AS. Analysis of mucins: role in laboratory diagnosis. J Clin Pathol 2008;61:1018–1024.
3. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68–73.
11. Jeong SJ, An M, Jang M, et al. Severity of COVID-19 associated with SARS-CoV-2 variants dominant period in the Republic of Korea. Public Health Weekly Report 2023;16:1464–1487.
13. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11:164–168.
14. Ohshimo S, Ishikawa N, Horimasu Y, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med 2014;108:1031–1039.
15. Yokoyama A, Kohno N, Kondo K, et al. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Respirology 1998;3:199–202.
16. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest 1995;108:311–315.
17. Wakamatsu K, Nagata N, Kumazoe H, et al. Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir Investig 2017;55:16–23.
20. Vianello A, Guarnieri G, Braccioni F, et al. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med 2021;60:307–316.